5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients.

          Related collections

          Author and article information

          Journal
          Anticancer Res.
          Anticancer research
          International Institute of Anticancer Research
          1791-7530
          0250-7005
          August 2017
          : 37
          : 8
          Affiliations
          [1 ] Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
          [2 ] Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan gouji104kawa@gmail.com.
          [3 ] Research Institute for Disease of the Chest Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
          [4 ] Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
          [5 ] Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
          [6 ] Department of Neuropathology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
          Article
          37/8/4223
          10.21873/anticanres.11813
          28739710
          abf4a3dc-6121-4b54-b5c1-ffdefb261c6c
          History

          non-small cell lung cancer,immunotherapy,Programmed cell death-ligand 1

          Comments

          Comment on this article